EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Osteokines in Nonalcoholic Fatty Liver Disease

Ilias D Vachliotis, Athanasios D Anastasilakis, Vasileios Rafailidis, Stergios A Polyzos

Current Obesity Reports · 03.09.2024 · 13 (4) · 703-723

DOI: 10.1007/s13679-024-00586-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Obesity Reports, online erschienen am 03.09.2024. Verfasst von Ilias D Vachliotis und 3 weiteren Autor:innen. Beteiligte Einrichtung: First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. ivachliot@auth.gr. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver, Osteocalcin, Fibroblast Growth Factor-23. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 155 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: To critically summarize evidence on the potential role of osteokines in the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD). RECENT FINDINGS: There are emerging data supporting that certain osteokines, which are specific bone-derived proteins, may beneficially or adversely affect hepatic metabolism, and their alterations in the setting of osteoporosis or other bone metabolic diseases may possibly contribute to the development and progression of NAFLD. There is evidence showing a potential bidirectional association between NAFLD and bone metabolism, which may imply the existence of a liver-bone axis. In this regard, osteocalcin, osteoprotegerin, bone morphogenic protein 4 (BMP4) and BMP6 appear to have a positive impact on the liver, thus possibly alleviating NAFLD, whereas osteopontin, receptor activator of nuclear factor kappa Β ligand (RANKL), sclerostin, periostin, BMP8B, and fibroblast growth factor 23 (FGF23) appear to have a negative impact on the liver, thus possibly exacerbating NAFLD. The potential implication of osteokines in NAFLD warrants further animal and clinical research in the field that may possibly result in novel therapeutic targets for NAFLD in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiverOsteocalcinFibroblast Growth Factor-23Bone and BonesHumansAnimalsOsteopontinOsteoprotegerinFibroblast Growth FactorsBone Morphogenetic Protein 4RANK LigandBone Morphogenetic Protein 6Bone Morphogenetic ProteinsAdaptor Proteins, Signal TransducingCell Adhesion MoleculesDisease Progression

Stichwörter der Autor:innen

BoneMetabolic dysfunction-associated steatotic liver diseaseNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisOsteokines

Substanzen

FGF23 protein, humanOsteocalcinFibroblast Growth Factor-23OsteopontinOsteoprotegerinFibroblast Growth FactorsSOST protein, humanBone Morphogenetic Protein 4RANK LigandPOSTN protein, human

Autor:innen und Institutionen

  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. ivachliot@auth.gr.
  • Department of Endocrinology, 424 General Military Training Hospital, Thessaloniki, Greece.
  • Department of Clinical Radiology, AHEPA University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. spolyzos@auth.gr.

Zitieren

APA

Vachliotis, I. D., Anastasilakis, A. D., Rafailidis, V., & Polyzos, S. A. (2024). Osteokines in Nonalcoholic Fatty Liver Disease. Current Obesity Reports, 13(4), 703-723. https://doi.org/10.1007/s13679-024-00586-9

Vancouver

Vachliotis ID, Anastasilakis AD, Rafailidis V, Polyzos SA. Osteokines in Nonalcoholic Fatty Liver Disease. Current Obesity Reports. 2024;13(4):703-723. doi:10.1007/s13679-024-00586-9

BibTeX
@article{Vachliotis2024,
  author = {Vachliotis, Ilias D and Anastasilakis, Athanasios D and Rafailidis, Vasileios and Polyzos, Stergios A},
  title = {Osteokines in Nonalcoholic Fatty Liver Disease},
  journal = {Current Obesity Reports},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {703--723},
  doi = {10.1007/s13679-024-00586-9}
}
Kostenlos starten →